Introduction
The spectrum of infectious agents that cause central nervous systemic (CNS) infections in remarkably broad, and the clinical spectrum ranges from acute, life-threatning diseases to chronic diseases with few or no symptoms. To obtain laboratory corroboration of correct diagnosis and to monitor an infection tend to be more complicated in CNS than in other sites, primarly because cerebrospinal fluid (CSF), the fluid closest to the brain, can be reached only by means of lumbar puncture . Under healthy conditions, no inflammatory activity is seen in CSF, and the cell count is low, whereas CNS infections frequently cause increased CSF cell counts. Number and characterization of CSF cells are valuable means of differentiating between infectious diseases and non-infectious diseases as well as between viral and bacterial CNS infections .
The expanding insight into cytokine release and activation of cell mediated immunity following an infection raises the question whether measuring substances associated with these reactions can provide further and improved information for clinical use in patients with CNS infections. The release of cytokines is a rapid event, mainly a communication between cell-to-cell. Measures of cytokines in extracellular fluids in established infections are thus far from always representative of the actual cytokine release. The time of sampling is often too late, i. e first when the effects of cytokines have already passed their maximum levels and are disappearing from the circulation. CyPteridines/ Vol. 6 / No. 4 tokines induce a variety of biological changes in target cells, changes which may provide more reliable information to follow than the concentrations of the cytokines themselves. However, the various tests to evaluate the status of cellmediated immunity are generally too complicated for routine clinical use.
The production of neopterin is closely correlated with activation of cell-mediated immunity (1) . Interferon gamma and tumor necrosis alpha ae the key cytokines triggering neopterin formation in macrophages. Therefore, neopterin monitoring is also a means of quantifYing the activation status of monocytes/macrophages and other cytokine producing cells, and it might be a clinically superior method for following a cytokine cascade than measuring of individual cytokines . Neopterin is biologically stable and it can easily be quantified in CSF and other human body fluids .
Although the estimated serum-to-CSF distribution of neopterin has assumed to be as minor as the quotient of 1/ 40 (2), the serum concentrations are only slighter higher than those in CSF in healthy indivduals. Furthermore, the CSF neopterin levels exceed the serum levels in the majority of CNS infections, which clearly shows the origination from an intrathecal production. This should be considered in conjunction with the fact that the number of mononuclear cells in CSF is normally 1,000 times less than in peripheral blood. What then is the source of the neopterin production in CNS? The CNS cells producing neopterin are not known, but the major candidates as present are infiltrating macroph age/monocytes and microglial cells.
The clinical use of cytokine determinations and me role of markers of infectious activity, such as neopterin in eSF, are currently under investigation but are rarely not used in clinical practice today . In the present review, eSF neopterin concentrations are taken into consideration as an indirect measurement of eNS infection and cyto kine activity ,and their potential clinical value is evaluated. The review will discuss studies using radioimmuno assay (RIA) as method to measure neopterin and not measuring of total neopterin (i.e. neopterin + dihydroneopterin).
CSF neopterin in healthy individuals
Normal values eSF concentrations of neopterin have been determined with RIA in several studies. We have previously reported eSF ne o pterin concentrations between 3.2 and 5.5 nmol/l ( mean 4.2 nmol/I) in 24 healthy controls ( 3 ) . GlimaIcer et al found that 20 indi viduals with a median age of 62 years, who were undergoing surgery, but had no eNS symptoms, showed a median value of 5 .6 nmol/l (4). I n another study ( 5 ) , the mean concentration was 3.5 nmol/ I in 7 individuals with non-int1ammatory eNS diseases. Other control groups, including 11 and 19 patients with headache or psychoneurotic disorders, had mean values of 1 .6 (6 ) and 3 .2 nmoljI , respectively (6 ), and 15 HN-negative patients with noninflammatory C~S disea se had mean CSF neopterin concentration of 2.3 nmoljl ( 2 ) . A significant positive correlation \vas seen between eSF neopterin levels and age ( 3 ). Therefore, the 95% prediction intervals for individual neopterin concentration vary with age . A eSF concentration above 3.4 nmol/l is regarded as the upper normal limit according to the manufacturer of a frequently used RIA test, a level which probably is too low. The upper limit of normal neopterin values in eSF was set at 9.8 nmol/l in patients undergoing surgery (4), a level which probably is too high, since lower values were recorded during the convalescent phase following enteroviral meningitis in the same study. Age-related upper limits of 5,5 nmol/l at 40 years of age and 6.5 nmoljl at 70 years of age were defined as abnormal among healthy volunteers in our previous studv ( 3 ) . The normal eSF concentration s o f neopterin were s()ll1l"\vhat lower than those in serum in Clur stud\· P()I,uhti()11 Ptcridil1cs / \'()1. 
CSF neopterin in infe~tious diseases
Increased levels of neopterin have been reported in the acute phase of a number of infections . The first reports on elevated eSF levels with intrathecal neopterin production were based on observations of patients with aseptic meningoencephalitis (6 ) . Reports from patients with HN infection followed soon thereafter (8, 9 ) . Elevated eSF levels were found both in neurologicallv asymtomatic HN-infected paticnts and in patients with neurological symtoms ( 3 ,S,8,9 ) . Elevated eSF levels have also been reported in patients with Lyme neuroborreliosis ( 7) , in patients \\lith purulent meningitis ( 3, 4, 10 ) , and in patients with viral encephalitis ( 3, 11 ) . In Figure I . CSF neopterin levels in a logarithmic scale are shown in a variety of acute eSF infections. Thc most pronounced elevation in the neopterin concentration was found in eSF sampled 2 days after the onset of eNS symptoms (4), which suggests that neopterin can be used as an acute phase reactant.
CSF neopterin in purulent bacterial meningitis
Acute purulent meningitis in previously healthy individuals is often caused by the bacteria Neisseria meningitidis, Haemophilus in{luenzae, or Streptococcus pneumonia . The infections arc charaterized by a vigorous immune response in the eSF with high numbers of mainly poly morphonuc1ear leucocytes. The mean eSF neopterin concentration were 63 .0 nmol/ l in 15 adult patients with acute bacterial meningitis in one study ( 3 ) and 90 nmoljl in children (10) . The median concentration was 86 nmoljl in another study (4 ) . The range of CSF neopterin concentrations was extremely wide in patients with bacterial meningitis ill these three studies ( 10-7 29 111l1()l/ l ' ) CSF neopterin in Lyme neuroborreliosis Lyme disease is caused by a spirochete, Borrelia 0urgdorferi, which is transmitted by ticks. In Eu-:-o pe. the most common extracutaneous man-::"cstation of the disease is chronic meningitis fre-.:uently causing cranial nerve palsy or radiculitic ;'dln. In our patients we have found that those ,-, ·:th the most severe disease had the highest CSF :-. eopterin concentrations (7) . CSF neopterin conentrations ranged from almost normal levels in ~:-:e patients who minor symtoms and were clin-:-::alh-improving to above 150 nmol/l in the pa-: ents with chronic, progressive, severe disease. -=-~e mean neopterin concentration in a group of :-atients with CSF pleocytosis was 54.9 nmol/l ,-" ' . Following antibiotic treatment, the CSF :-.copterin concentrations decreased in parallel ,.~th clinical improvement, and decreasing num--c: r of CSF monocytes and protein concentration The levels did not reach normal levels within -:-:lonths. In that study, the CSF neopterin con-:entrations did not add any information of more ~ ::nical use than that obtained by determination ~. CSF mononuclear cell counts and CSF protein : (I ncentrations.
CSF neopterin in patients with IllV/AIDS
Several studies have shown that HIV infects the c:~S early in the infectious course (12, 13) . Po-, ;ti"e CSF HIV isolation is common in asymp-: o matic HIV positive patients, and by use of PCR, :-IIY DNA has been detected in the vast majority ( )f the patients (14) . In a longitudinal study cove ring in mean, 43 months, and including 19 .?s,'mptomatic HIV-seropositive patients, the CSF n eopterin concentrations increased from, in mean, :~7 to 20 .4nmol/l (p<O.OI) (15) tients with cerebral toxoplasmosis, as compared to 21 nmol/l in patients with HIV encephalopathy, and 13 nmol/l in asymptomatic HIV-infected patients (2). In our experience, AIDS patients with CMV encephalitis had higher CSF neopterin concentrations than patients with toxoplasma encephalitis or progressive multifocal encephalopathy. Brain lesions found by magncetic resonance imaging technique have been signficantly correlated to elevated CSF neopterin levels (6). However, no data are yet showing that increased levels of CSF neopterin may serve as a predictor of subsequent AIDS dementia.
CSF neopterin foUowing antiretroviral treatments in patients with HIV / AIDS
An optimal anti-HIV treatment must involve the brain even in asymptomatic HIV-infected in- dividuals. Surrogate markers of HIV aCTIVIty may in this context play an important role in the investigation of the effect on the brain by various antiretroviral agents. After 4-8 months on zidovudine treatment in a group of 10 patients, there was a significant reduction of mean eSF neopterin (-53%, P < 0.01), which remained at the lower level also during the second year on treatment ( 17) . A significant reduction of eSF neopterin concentrations by zidovudine after a mean interval of 8 weeks was also reported by Brew et al in 9 patients ( 5) . Gulevich et al found that neopterin levels were lower in patients taking zidovudine for up to 1 year than in those who had received it for longer periods of time ( 18) . Little is known about how long the effects of zidovudine on eSF neopterin levels last, and about how the development of zidovudine-resistant virus isolates affects the intrathecal immune response. Our preliminay data indicate that development of zidovudine-resistant virus isolates has no major impact on the CSF neopterin levels . In figure 2 , the CSF neopterin concentrations in 14 patients before and after 3 -12 months (mean 7.5 months ) on zidovudine treatment is shown. All patients had a marked reduction of CSF neopterin concentrations. No reduction in CSF neopterin concentrations was seen on didanosinc treatment, an an tire troviral therapy which also exerts its efiect on reversed transciptase (Figure 3 ) . The reduced immune aCTIVlty following zidovudine treatment must be interpreted as beneficial for the patient. There was no other prognostic marker other than 132-microglobulirJ for evaluation of the efiect of treatment. Other parameters in serum used to estimate the virus load, such as p24 antigen are rarey present in eSF, and eSF-eD4 cells are fragile and hardly possible to count in clinical practice . Therefore, the eSF neopterin concentrations may be an important test to evaluate the effect of anti-retroviral treatment in the brain.
CSF neopterin in patients with viral meningo-encephalitis
Viral meningo-encephalitis is most commonly caused by herpesviruses . Mental changes, paresis, or seizures difierentiate this syndrome from acute viral meningitis. Herpes simplex encephalitis is one the most severe of all human virus infections in the CSf . Immediate treatment with acyclovir reduces the mortality dramatically. Therefore, rapid diagnostic procedures are of vital importance.
Pteridincs/ Vnl. 6 / No. 4 Viral meningo-encephalitis induces the highest neopterin response in eSF of all eNS infections studied. In 5 patients with different types of viral meningo-encephalitis, the mean eSF neopterin concentration was 130 .9 (range 86.4-236) ( 3). eSF concentrations of 15 of 17 surviving patients with Herpes simplex virus type 1 encephalitis had higher levels than 100 nmol/I. Even higher levels were found in the eSF in 15 patients who died in the disease (11) . Persistent intrathecal production of neopterin was seen several years after acute herpes simplex encephalitis, which has raised the question if the current treatment period of 10-14 days with acyclovir is sufficient, and if antiinflammatory therapy should complement antiviral treatment in this severe disease. Futher studies of the role of eSF neopterin concentration in late stages of Herpes type 1 encephalitis are urgently needed.
CSF neopterin in patients with viral meningitis
Patients with viral meningitis often present \vith sympoms of fever, nausea, and neck stifiness, but they show no altered conscious and no p aresis. Enterovirus is a common etiological agent in \'iral meningitis . Another frequent cause o f \'i ral meningitis is that it is developed as a complication to a recurrent Herpes simplex virus type 2 inkction. The mean eSF neopterin concentrations in patients with viral menjngitis have been estimated to 32.5 (6) and to 13 .9 nmol/l ( 3). Glirnaker et al (4) found significantly higher median eSF values of neopterin in cases with viral meningitis ascribed to Herpes simplex type 2 and to Varicella zoster virus (37.6 nmol/l ) than patients with an enteroviral etiology (20 .2 nmol/l ). However, the neopterin levels failed to discriminate between different etiological groups due to considerable overlap. Normalized levels were found in the convalescent phase in almost all tested patients (4, 6) . P16
CSF neopterin in patients with neurocysticercosis
Neurocysticercosis is an infection with larval cysts of the cestode T solium causing headache and seizures. Moderately elevated levels of eSF neopterin were seen in patients with neurocysticercosis (median 6.8 nmoljl ). One year after praziquantel treatment, eSF neopterin levels had decreased to a median value of 2.1 nmoljl ( 19) .
CSF neopterin compared with other infectious markers
Since neopterin prodution has been associated with monocyte and macrophage activity, the relationship between CSF monocytic cell count and CSF neopterin concentrations has been studied. Neopterin levels in CSF correlated with mononuclear cell count in patients with aseptic meningitis (3,4,6) but not in other patients with CNS diseases. In AIDS, all patients had elevated CSF neopterin levels without concomitant CSF pleocytosis .
Neopterin is correlated to 13-2 microglobulin levels in larger clinical populations . Although 13-2 microglobulin and neopterin concentrations often correlate, they do not measure the same activation mechanisms of the immune system. In a study comparing 13-2-microbglobulin and neopterin CSF concentrations in aseptic meningitis, the neopterin were considerably more consistently and markedky elevated 13-2 micro globulin (4 ) . Thus, neopterin appears to be more sensitive III CSF than 13-2 microgloblin to infections.
CSF neopterin in non-infectious CNS diseases
The CSF concentrations of neopterin were moderately elevated in patients with multiple sclerosis, mean 2.1 (6) and 9 .1 nmol/I (20) in clinical remission compared with 1.25 and 3.4 nrnol/ l in non-inflammatory controls. Slightly higher levels were seen during exacerbations of MS (21) . Post-measels encaphalomyelitis is regarded as an autoimmue demyelinating disease triggered by measles virus infection. In 5 patients with measles encephalomyelitis, Griffin et al ( 22) found neopterin CSF levels ranging from normal levels to 60 nmol.I (mean 20 nmol/I). Little is known about CSF neopterin and CNS tumours. Six AIDS patients with brain lymphoma had CSF neopterin concentration of, in mean, 34.8 nmol/l (5), but to what extent this increase was attributable to the lymphoma contributed or to the AIDS could not be evaluated . There were no increased CSF neopterin concentrations in Parkinson's disease (23) . In patients with subarachnoid hemorrhage, neopterin concentrations were elevated in CSF (up to 95 nmol/I), with the highest levels registered on day 9 (24).
Conclusions
Neopterin is produce intrathecally in all CNS infections studied and represents an unspecific immune activation. The neopterin concentrations in different CNS infections showed considerable overlap. Although ptients with viral encephalitis had higher mean neopterin levels than any other patient category studied, the CSF neopterin concentrations could not discriminate between viral and bacterial CNS infections. However, low levels of CSF neopterin in an encephalitic patient suggest that Herpes simplex type 1 is less likely as the etiological agent. The CSF neopterin concentrations may be useful for differentiation between inflammatory and non-inflammatory CNS diseases. The levels of the substance may thus be used as a complement to white cell counts and protein concentrations as markers for cellular immune response, and it can in some types of infections indicate the severity, but not the etiology, of the diseases.
In HIV infection, CSF neopterin levels may have an important role in monitoring of the treatment effects of antiretroviral therapies in the CNS . Especially in AIDS patients, the number of CSF cells is a poor marker of disease activity. There is currently no laboratory marker in blood or CSF that definitely predicts the risk for HIV-I-associa ted cognitive/motor complex, which remains a clinical diagnosis. Whether a high concentration of neopterin predicts AIDS dementia is not yet determined.
Elevated neopterin levels perslstmg for a long time after an Herpes type 1 encephalitis may indicate a latent ongoing infection and thereby reflect a need for longer treatment regimens. However, also in patients with neurobrreliosis, moderately elevated levels were seen in CSF several months after succesful treatment. In these cases, there was no suspicion of latent living spirochetes in the CNS, which may imply that a triggered cellular immune response in the CNS is kept up for a long time. Rapid normalization of CSF neopterin was seen in patients with bacterial and aseptic meningitis. The clinical role of persistent production of CSF neopterin in some CNS lllfections is not clear at present.
In a number of infectious diseases, the most severe toxic effect is not caused by the microorganism itself but by the host's own immune response . An adverse immune response with excessive production of cytokines is reflected by high neopterin levels . In addition to providing clinically useful information, neopterin monitoring could give infomation about the pathogenicity of a variety of diseases.
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Introduction
Pterins are found in three oxidation states in nature: the oxidized, the dihydro, and the tetrahydro form (1, 2) . The latter is the most biologically active one, as demonstrated by the extensively studied L-erythro-5,6,7,8-tetrahydrobiopterin (H4Bip ) (3), which functions as the electron donor for mixed function oxidases such as phenylalanine (PAH), tyrosine (TH), and tryptophan (TrpH) hydroxylase during biogenic amine biosynthesis (4, 5 ) . The binding of 6 -methyl-5,6,7,8 -tetrahydropterin to human recombinant TH1 (hTH1) has recently been shown by lH-NMR studies (6) , indicating that photo affinity labeling with an appropriately substituted analog may be a useful approach to characterize the cofactor binding site in the enzyme . The design of an azido analogue of 6-phenyl-tetrahydropterin for the photoaffinity labeling of PAR has been described (7) . A close structural analog to the natural cofactor H4Bip was seen in the 6-azidomethyl-5 ,6 ,7,8-tetrahydropterin (6-AzmH4Ptr) (9) . The synthesis of (6-AzmH 4 Ptr) and some of its photodegradation products will be described in this paper.
Results and Discussion
The synthesis of 6-azidomethyl-5,6,7,8-tetrahy-
